Evaluation of gastrointestinal symptoms and effectiveness of Rikkunshito for them after endoscopic submucosal dissection for gastric neoplasms

Evaluation of gastrointestinal symptoms and effectiveness of Rikkunshito for them after endoscopic submucosal dissection for gastric neoplasms - Rikkunshito and gastrointestinal symptoms following ESD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002302

Enrollment

Registered

2009-08-07

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Rikkunshito group PPI accompanied with Rikkunshito for 8 weeks 7.5g per day only PPI

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with gastric cancer who underwent ESD inclusion criteria 20-80 years old The guidline or expanded lesions for ESD After obtaining informed consent

Exclusion criteria

Exclusion criteria: EGCs who did not fall into one of the categories were excluded from the study

Design outcomes

Primary

Measure	Time frame
Gastrointstinal symptoms associated with ESD Efficacy of Rikkunshito for upper gastrointestinal symptoms comaparison of efficacy for the symptoms by PPI with our without Rikkunshito	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026